A novel splice variant of Rac1, designated Rac1b, is expressed in human breast and colon carcinoma cells. Rac1b contains an additional 19 amino-acid insert immediately behind the switch II domain, a region important for Rac1 interaction with regulators and effectors. Recent studies showed that Rac1b exhibited the biochemical properties of a constitutively activated GTPase, yet it showed impaired interaction with downstream effectors, suggesting that Rac1b may be defective in biological activity. Whether Rac1b is a biologically active protein was not addressed. Therefore, we evaluated the biochemical, signaling and growth-promoting properties of authentic Rac1b. Similar to previous observations, we found that Rac1b showed enhanced intrinsic guanine nucleotide exchange activity, impaired intrinsic GTPase activity, and failed to interact with RhoGDI. Surprisingly, we found that Rac1b, like the constitutively-activated and transforming Rac1(Q61L) mutant, promoted growth transformation of NIH3T3 cells. Rac1b-expressing cells also showed a loss of density-dependent and anchorage-dependent growth. Surprisingly, unlike activated Rac1(61L), Rac1b did not show enhanced activation of the nuclear factor jB (NF-jB) transcription factor or stimulate cyclin D1 expression, the signaling activities that best correlate with Rac1 transforming activity. However, Rac1b did promote activation of the AKT serine/threonine kinase. Therefore, we suggest that Rac1b selectively activates a subset of Rac1 downstream signaling pathways to facilitate cellular transformation.
Introduction
The human Rho family of small guanosine triphosphatases (GTPases) is comprised of 22 members, and includes Cdc42, Rac1 and RhoA, which regulate actin reorganization and the formation of filopodia, lamellipodia and stress fibers, respectively (Ridley, 2001; Etienne-Manneville and Hall, 2002; Van Aelst and Symons, 2002) . In addition to their regulation of actin cytoskeletal dynamics, Rho family proteins also regulate signaling pathways that control gene expression and progression through the cell cycle (Hill et al., 1995; Minden et al., 1995; Sulciner et al., 1996; Roux et al., 1997; Westwick et al., 1997) . Rac1, for example, stimulates activation of the NF-kB and serum response factor (SRF) transcription factors, as well as the Jun NH 2 -terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) signal transduction pathways that lead to the activation of AP1 transcription factors (Van Aelst and D'Souza-Schorey, 1997; Bar-Sagi and Hall, 2000) . These transcription factors then upregulate the expression of cell cycle regulatory proteins, such as cyclin D1, that promote G1-to S-phase progression. In addition, activated Rac1 has been shown to stimulate phosphatidylinositol-3 kinase (PI3K)-dependent activation of the AKT serine/threonine kinase (Keely et al., 1997; Coniglio et al., 2001; Rul et al., 2002; Wennerberg et al., 2002) . This implicates Rac1 in antiapoptotic signaling and provides a mechanism by which aberrant Rac1 activity can promote cellular transformation.
Rho GTPase function is regulated by three classes of regulatory proteins. Rac1, like other small GTPases, cycles between inactive GDP-bound and active, GTPbound states. The exchange of GDP for GTP is promoted by guanine nucleotide exchange factors (GEFs) that include Dbl family proteins (e.g., Tiam1). The inactivation of small GTPases is also under regulatory control by GTPase activating proteins (GAPs) that enhance the hydrolysis of bound GTP to GDP and inorganic phosphate (e.g., BCR) (Moon and Zheng, 2003) . Guanine nucleotide dissociation inhibitors (GDI), for example RhoGDI-1/Rho-GDIa, comprise a third class of regulatory proteins that sequester Rho GTPases in the cytosol in a GDP-bound, inactive state.
By analogy to the Ras oncogene product, genetically engineered mutants of Rac1 acquire transforming potential. For example, G12V or Q61L mutants of Rac1 are impaired in intrinsic and GAP-stimulated GTPase activity (Xu et al., 1997) and the Rac1(61L) mutant is also unresponsive to RhoGDI inactivation (Michaelson et al., 2001) . In contrast, the F28L mutation enhances Rac1 intrinsic exchange activity and results in a fast cycling mutant (Lin et al., 1999) . Both GTPase-deficient and fast cycling Rac1 mutants can cause growth transformation (Khosravi-Far et al., 1995; Qiu et al., 1995; Lin et al., 1999) . To date, however, unlike Ras, direct mutational activation of Rac1 and other Rho GTPases in human cancers has yet to be identified (Boettner and Van Aelst, 2002; Jaffe and Hall, 2002; Sahai and Marshall, 2002) . For example, we previously analysed breast cancer tissue and breast cancer cell lines and did not find any mutations of Rac1 (Jordan et al., 1999; Schnelzer et al., 2000) .
Recently, a splice variant of the Rac1 gene was found to be expressed in breast and colon carcinomas (Jordan et al., 1999; Schnelzer et al., 2000) . This variant, designated Rac1b, was found to be overexpressed in malignant colon carcinomas both at the RNA and protein levels, when compared to levels in benign tissue. The Rac1b transcript contains an additional 57 nucleotides, which encodes a protein with an in-frame insertion of 19 amino acids between Rac1 residues 75 and 76 and positioned immediately carboxyl-terminal to the switch II domain. The switch II domain (Rac1 residues 60-76), along with the switch I domain (Rac1 residues 30-38), constitute the regions that change in conformation during GDP/GTP cycling. These regions are also important for Rac1 interaction with regulators and effectors (Vetter and Wittinghofer, 2001) . Hence, the Rac1b insert sequence may alter the intrinsic biochemical properties, as well as interaction with regulators and effectors. Consistent with this possibility, Matos et al. (2003) and Fiegen et al. (2003) determined that Rac1b possessed impaired intrinsic GTPase activity, yet it retained GAP responsiveness in vitro and in vivo. Thus, unlike the G12V or Q61L mutants of Rac1, Rac1b can still be inactivated by GAP activity. Matos et al. (2003) also reported that RhoGDIa failed to bind Rac1b. However, conflicting observations were made regarding the ability of Rac1b to interact with GEFs. Matos et al. (2003) reported that Rac1b was GEF-responsive in vivo, whereas Fiegen et al. (2003) found that Tiam1 DH/PH did not accelerate Rac1b nucleotide dissociation in vitro. Additionally, whether Rac1b is altered in interaction with downstream effectors has not been clarified. Matos et al. (2003) found that a Q61L mutant of Rac1b was unable to induce lamellipodia and to activate p21 activated kinase (PAK) and JNK. However, since this mutation alters switch II conformation, whether authentic Rac1b is similarly impaired in effector function remained unclear. Finally, despite biochemical properties consistent with an activated protein, the failure of the Q61L mutant of Rac1b to activate downstream signals, argues that Rac1b is not a biologically active protein. Therefore, some of the biochemical properties of Rac1b are still unclear, and whether this tumor-associated Rac1 variant can contribute to oncogenesis remains unanswered.
In this study, we found that, like Rac1(61L), Rac1b caused growth transformation of NIH 3T3 cells. Rac1b-expressing cells exhibited focus-forming activity, and loss of density-dependent and anchorage-dependent growth. Surprisingly, unlike Rac1(61L), Rac1b was unable to stimulate a number of canonical downstream effector activities (lamellipodia induction, JNK activation, PAK binding), including stimulation of NF-kB transcriptional activity or cyclin D1 expression. However, we did find that Rac1b, like Rac1(61L), promotes AKT activation. Thus, Rac1b exhibits selective downstream signaling activity, and activation of AKT may contribute to Rac1b promotion of cellular transformation.
Results

Rac1b exhibits a high intrinsic guanine nucleotide exchange activity that is not further stimulated by Tiam1
In agreement with our previous analyses (Schnelzer et al., 2000) , two recent studies also determined that Rac1b exhibited a higher rate of intrinsic guanine nucleotide exchange in vitro when compared to wild-type (WT) Rac1 (Fiegen et al., 2003; Matos et al., 2003) . However, conflicting observations were made regarding the ability of Tiam1 to further stimulate Rac1b exchange activity. To attempt to resolve this issue, we performed in vitro guanine nucleotide exchange assays to determine if Rac1b was able to undergo increased exchange in the presence of the Tiam1 Rac-specific GEF. We also included analyses of a second Rac GEF, Vav, which also activates RhoA, RhoG and Cdc42. Bacterially expressed GST fusion proteins of each Rac1 protein and the catalytic fragments of Tiam1 (DH/PH domains) and Vav2 (DH/PH/CRD domains) were used for these analyses (Worthylake et al., 2000; Booden et al., 2002) . Rac1 WT exchanged GDP for mant-GTP at a slow rate and this was enhanced significantly by both Tiam1 and Vav2 (Figure 1) . GST-Rac1b, on the other hand, exhibited a much higher intrinsic guanine nucleotide exchange that was not accelerated further when Tiam1 DH-PH or Vav2 DH/PH/CRD was added. We also failed to see Rac1b activation when the constitutively activated form of Tiam1 (C-1199) was ectopically expressed in NIH 3T3 cells (data not shown). Thus, our results are in agreement with those of Fiegen et al. (2003) .
We next wanted to determine whether the inability of Tiam1 to accelerate exchange on Rac1b was due to a failure to associate with the GTPase. For these analyses, we evaluated the ability of glutathione-S-transferase (GST) fusion proteins of each Rac1 protein to complex with a constitutively activated form of Tiam1 (C-1199) in vitro ( Figure 1b) . As expected, Tiam1 associated preferentially with nucleotide-free (NF), and not with guanylyl-5-imidodiphosphate (GMPPNP; a nonhydrolysable GTP analogue) bound, Rac1 WT. In contrast, Tiam1 stably associated with both nucleotide-free (NF) and GMPPNP-loaded Rac1b, but at a reduced level when compared with Rac1 WT. Thus, the inability of Tiam1 to stimulate Rac1b guanine nucleotide exchange is not due to loss of binding.
Rac1b is impaired in intrinsic GTPase activity and RhoGDI interaction Matos et al. (2003) found that ectopic expression of BCR, a Rac GAP, caused a reduction in Rac1b GTP binding, indicating that Rac1b could still interact with GAPs. However, no in vitro analyses with purified proteins were shown. Therefore, we performed these analyses. When compared to Rac1 WT, Rac1b exhibited a greatly impaired ability to hydrolyse GTP in vitro (Figure 2) . Furthermore, the addition of BCR, a RacGAP, which significantly promoted Rac1 WT GTP hydrolysis, also stimulated Rac1b GTP hydrolysis, but at a reduced level when compared to Rac1 WT. These findings are consistent with those of Matos et al. (2003) and Fiegen et al. (2003) , and we conclude that Rac1b can still be stimulated by GAPs. Similar to Matos et al. (2003) , we also found that Rac1b was impaired in interaction with RhoGDIa in vitro and in vivo (Figure 3a and b). This property is similar to that of the GTPase-deficient and transforming Rac1(61L) mutant protein, which also remained membraneassociated with RhoGDIa expression.
Rac1b promotes growth transformation of NIH 3T3 cells
Since our analyses indicated that Rac1b exhibits biochemical properties associated with constitutively Figure 1 Rac1b exhibits enhanced intrinsic guanine nucleotide exchange activity that is not accelerated by Tiam1 in vitro. (a) In vitro fluorescence-based guanine nucleotide exchange assays were done to determine the rates of intrinsic and Tiam1 catalysed exchange on bacterially expressed GST fusion proteins of Rac1b and Rac1WT. Purified recombinant fusion proteins, preloaded with GDP, were incubated with mant-GTP. Intrinsic or catalysed exchange was measured as an increase in relative fluorescence, as mant-GTP became bound to each respective GTPase. Bacterially expressed Tiam1 DH/PH (0.2 mM) or Vav2 DH/PH/CRD (0.2 mM) was added after 300 s. (b) Rac1b can still associate with Tiam1 in vitro. GST-Rac1WT or Rac1b were rendered nucleotide-free (NF) by treatment with 10 mM EDTA or were bound with 2 mM GMPPNP, a nonhydrolysable GTP analog. Fusion proteins bound to beads were added to cell lysates containing Myc-Tiam1(C-1199). (c) Bound Myc-Tiam1(C-1199) was then detected by resolving proteins by SDS-PAGE followed by immunoblotting with antiMyc antibody (9E10). Data shown are representative of three independent experiments Figure 2 Rac1b exhibits impaired intrinsic and GAP-stimulated GTPase activity. In vitro GTPase assays were performed by measuring the accumulation of inorganic phosphate as a result of GTP hydrolysis. Recombinant GST-Rac1 WT and Rac1b were loaded with GTP by incubation with 2 mM GTP in the presence of 10 mM EDTA followed by 40 mM Mg 2 þ to facilitate guanine nucleotide exchange. Fusion proteins were then eluted from the beads with 100 mM glutathione. GTP hydrolysis was measured as changes in PBP fluorescence with a l ex ¼ 426 nM and l em ¼ 464 nM. GAP-stimulated activity was measured using 0.1 mM recombinant GST-BCR-GAP. Data shown are representative of three independent experiments active GTPases, we wanted to determine if it had enhanced transforming properties compared to Rac1 WT. For these analyses, we performed various NIH 3T3 transformation assays and utilized the transforming, GTPase-deficient Rac1(61L) mutant as a positive control. We and others have established previously that GTPase-deficient mutants of Rac1, such as G12V and Q61L, can promote key aspects of cellular transformation when expressed in NIH 3T3 and other cell types, and include causing a loss of density-dependent inhibition of growth and the acquisition of anchorageindependent growth (Khosravi-Far et al., 1995; van Leeuwen et al., 1995; Tolkacheva et al., 1997; Westwick et al., 1997) .
We first used two different focus formation assays to assess whether Rac1b could promote loss of density-dependent growth inhibition. Activated Rac1(61L), but not WT, can cooperate with activated Raf to cause synergistic focus-forming activity (Khosravi-Far et al., 1995; Qiu et al., 1995; Lin et al., 1999) . Similar to Rac1(61L), we determined that Rac1b cooperated with Raf-1(Y340D) and caused a six-fold greater frequency of focus formation than seen with Rac1 WT (Figure 4a and b). This activity was comparable to that seen with Rac1(61L), which exhibited a nine-fold enhancement in focusforming activity. Similar results were seen in a secondary focus formation assay using NIH 3T3 cells stably expressing each Rac1 protein, where Rac1b and Rac1(61L) caused six-and 10-fold enhanced focusforming activities, respectively, when compared to Rac1 WT (Figure 4c and d). The enhanced transforming potential of Rac1b was not due to greater expression, since the level of Rac1b was similar or less than that seen for Rac1 WT or Rac1(61L) (Figure 4e ). Finally, the appearance of cells in foci of transformed cells caused by Rac1b was essentially the same as that of cells in foci caused by Rac1(61L) and consisted of nonrefractile cells Figure 3 Rac1b fails to undergo cytosolic sequestration by RhoGDIa. (a) Coexpression of myc-Rho-GDIa does not reduce Rac1b plasma membrane association. MDCK cells were transiently transfected with the indicated plasmid constructs encoding GFP alone or GFP-Rac1 proteins, together with pRK5-myc empty expression vector or pRK5-myc encoding Myc epitope-tagged RhoGDIa. Cells were then fixed and stained with mouse anti-Myc (9E10) antibody followed by AlexaFluor594 conjugated anti-mouse secondary antibody. (b) Rac1b fails to bind to RhoGDIa in vitro. GST, GST-Rac1 WT and GST-Rac1b bound to glutathione-sepharose beads were incubated with lysates of cells ectopically overexpressing Myc epitope-tagged RhoGDIa. Bound Myc-Rho-GDI1 was detected by SDS-PAGE followed by immunoblotting using the anti-Myc (9E10) antibody. Data shown are representative of three independent experiments that formed multilayered clusters of tightly packed cells (Figure 4f) .
We next evaluated the growth rate and saturation density of NIH 3T3 cells stably expressing each Rac1 protein. Whereas Rac1(61L) caused an enhanced rate of growth when compared to Rac1 WT, the rate of growth caused by Rac1b was similar to that of Rac1 WTexpressing cells. However, consistent with the enhanced focus-forming activity of Rac1b-expressing cells, we found that these cells reached a higher saturation density than cells expressing Rac1 WT, but this level was less than that seen with cells expressing Rac1(61L) (Figure 5a ).
Finally, we determined the ability of Rac1b to promote anchorage-independent growth. Whereas Expression levels of the pCGN-hygro Rac1 constructs vary in stably transfected NIH3T3 cells. The expression of HA epitope-tagged Rac1 proteins was detected using an anti-HA antibody. (f) The appearance of Rac1b and Rac1(61L) foci was assessed by bright-field microscopy Rac1(61L)-expressing cells formed five-fold more colonies than Rac1 WT-expressing cells when suspended in soft agar, Rac1b-expressing cells showed an intermediate frequency that was approximately two-fold higher than the frequency seen with Rac1 WT-expressing cells (Figure 5b and c) . Taken together with enhanced focusforming activity of Rac1b, we conclude that this splice variant is an activated and transforming variant of Rac1 WT. The transforming activity seen was quantitatively less than that seen with Rac1(61L). The transforming activity seen with Rac1b is unexpected in light of the impaired effector signaling activity seen with a Q61L mutant of Racb1b (Matos et al., 2003) .
Rac1b exhibits selective downstream signaling activity Matos et al. (2003) showed that a Q61L mutant of Rac1b did not induce lamellipodia or activated PAK in SW480 human colorectal carcinoma cells. Since the Q61L substitution perturbs switch II domain function, whether authentic Rac1b is impaired in these activities is not clear. Furthermore, in light of cell context differences in Rho GTPase function, we also wanted to complement our transformation studies done in NIH 3T3 cells with signaling analyses done in the same cell type. We first evaluated the ability of Rac1b to induce actin reorganization and cause formation of lamellipodia. We performed fluorescence microscopic analyses on TRITC-phalloidin-stained NIH 3T3 cells stably expressing each Rac1 protein ( Figure 6 ). Unlike cells expressing Rac1(61L), Rac1b-expressing cells failed to form lamellipodia. Additionally, whereas Rac1(61L) caused activation of JNK, like Rac1 WT, Rac1b did not stimulate JNK activation (Figure 7a) . Furthermore, we also found that, Rac1b did not exhibit enhanced ability to promote the transcriptional transactivation of NF-kB and transcription from the cyclin D1 promoter when compared to Rac1(61L), which potently activates these signaling pathways (Figure 7b and c) .
The impaired effector activation seen with Rac1b may be due to impaired ability to bind effectors. To clarify this issue, we evaluated the ability of Rac1b to interact with effectors using an in vitro binding assay with GSTRac1 proteins and lysates of NIH 3T3 cells transiently expressing a known Rac1 effector protein. Consistent with previous observations, we found that Rac1 WT showed GTP-dependent association with full-length Pak1 as well as with the isolated Rac-GTP binding domain (RBD)-containing fragment of another Rac1 effector, Posh (Figure 7d ) (Tapon et al., 1998) . In contrast, Rac1b displayed greatly reduced association with both Pak1 and Posh-RBD. Thus, the reduced Figure 6 Rac1b fails to induce the formation of lamellipodia in NIH 3T3 cells. NIH 3T3 cells stably expressing each of the indicated Rac1 proteins were plated onto glass coverslips, fixed in 3.7% formaldehyde and permeabilized in 0.5% Triton X-100. Actin was then visualized with 50 mM TRITC-conjugated phalloidin. Fluorescence microscopy was then carried out using a Zeiss Axioscope equipped with a Rhodamine filter, to detect membrane ruffling/lamellipodia formation. Expression of Rac1 proteins in the stable cell lines was verified by immunoblotting as described above (e) Rac1b exhibits impaired effector association. NIH 3T3 cells were transfected with expression vector plasmids encoding the indicated CRIB motif containing effector peptides. Cell lysates were then incubated with GST-Rac fusion proteins bound to glutathione-agarose beads that were either untreated (GDP bound) or treated with 1 mM GMPPNP (a nonhydrolysable GTP analog). GST-Rac complexes were pulled down and bound effector peptides were detected by SDS-PAGE followed by immunoblotting with the indicated probes. Data shown are representative of three independent experiments. (f) Rac1b activates AKT by promoting its phosphorylation on serine 473. NIH 3T3 cells were transiently transfected with empty pCGN-hygro vector or pCGN-hygro encoding the indicated Rac1 proteins. Phospho-AKT levels were then detected by SDS-PAGE followed by immunoblotting with anti-phospho-AKT (ser473) antibody. Total AKT was detected with a polyclonal anti-AKT antibody. (g) Quantitation of data shown in panel (f) above. Data shown are representative of three or four independent experiments signaling and transforming activity seen with Rac1b, when compared to Rac1(61L), could be explained by the reduced ability to interact with known downstream effectors of wild-type Rac1.
Finally, we evaluated the ability of Rac1b to activate AKT, an activity that mediates various aspects of Rac1-mediated transformation (Keely et al., 1997; Coniglio et al., 2001) . Surprisingly, we found that Rac1b stimulated phosphorylation and activation of AKT at a level comparable to that promoted by Rac1(61L) (Figure 7f and g ) and significantly higher than the level promoted by Rac1-WT. Therefore, Rac1b differentially stimulates downstream signaling pathways activated by Rac1(61L).
Discussion
Rac1b was identified initially as a splice variant of Rac1 that is preferentially expressed in breast and colon cancers (Jordan et al., 1999; Schnelzer et al., 2000) . The 19 amino-acid insert sequence present in Rac1b is positioned immediately downstream of switch II, a region known to be involved in effector binding (Bishop and Hall, 2000) as well as interactions with regulatory proteins such as GEFs and GDIs (Ihara et al., 1998; Worthylake et al., 2000; Grizot et al., 2001; Karnoub et al., 2001) . Consistent with this possibility, two recent studies found that Rac1b was impaired in RhoGDI and PAK effector, but not GAP, interaction. However, conflicting observations were made regarding whether Rac1b was altered in GEF interaction. Additionally, Rac1b was found to exhibit enhanced intrinsic nucleotide exchange and impaired intrinsic GTP hydrolysis activity. While these properties support the possibility that Rac1b is biologically activated, the observations that a Q61L mutant of Rac1b was impaired in multiple, effector-dependent processes argue that Rac1b is an inactive protein. However, neither study evaluated Rac1b for biological activity. We found unexpectedly that, similar to activated variants of Rac1, Rac1b exhibited enhanced ability to cause growth transformation. However, unexpectedly, when compared to Rac1(61L), we also found that Rac1b was impaired in effector binding, stimulation of actin reorganization, and activation of JNK, NF-kB, and cyclin D1, but surprisingly not AKT. We conclude that Rac1b selectively activates only a subset of Rac1 effector functions, and suggest that AKT activation may be important for Rac1b-mediated transformation.
The switch II domain is important for Rac1 interaction with Tiam1 (Worthylake et al., 2000) . However, whereas Matos et al. (2003) reported that Rac1b retained the ability to co-precipitate with Tiam1 C1199 and presented indirect evidence that Rac1b was GEF-responsive in vivo, Fiegen et al. (2003) found that Tiam1 DH/PH did not accelerate Rac1b nucleotide dissociation in vitro.
In agreement with the later study, we found that Rac1b was unresponsive to Tiam1 and additionally Vav2 GEF-mediated exchange in vitro, and to Tiam1 C-1199 activation in vivo (data not shown). Thus, we conclude that Rac1b is not responsive to Tiam1 and Vav2.
In agreement with Matos et al. (2003) and Fiegen et al. (2003) , we also determined that Rac1b possessed impaired intrinsic GTPase activity but retained GAP responsiveness in vitro. Thus, GAP-responsiveness alone may not be sufficient to offset the enhanced intrinsic exchange and impaired intrinsic GTPase activities of Rac1b, thereby favoring the GTP-bound state (Matos et al., 2003) . However, it remains possible that upregulation of Rac GAP activity may still be one mechanism by which Rac1b activity can be modulated.
Given that Rac1b can become GTP-bound and activated in the absence of a GEF, fails to hydrolyse GTP at a rate comparable to Rac1 WT and remains persistently membrane associated, we speculated that Rac1b is constitutively active and would have oncogenic properties in vivo. Indeed, we found that Rac1b caused growth transformation of NIH3T3 cells. Like Rac1(61L), Rac1b showed enhanced focus-forming activity, and caused a loss of densitydependent and anchorage-dependent growth regulation, when compared to Rac1 WT. Thus, the expression of Rac1b may contribute to the aberrant growth properties of Rac1b-expressing breast and colon carcinoma cells.
Our observation that Rac1b is a transforming protein is surprising in light of the observations by Matos et al. (2003) that a Q61L variant of Rac1b was impaired in a variety of effector-mediated processes, including induction of lamellipodia and activation of PAK. However, these analyses were done with a mutant of Rac1b and whether authentic Rac1b was impaired similarly in effector activation was not clear. Therefore, we evaluated the ability of a wild-type version of Rac1b to activate various downstream effector functions. Similar to the studies by Matos et al. (2003) , we found that Rac1b was unable to induce lamellipodia and to activate PAK and JNK. However, they found that Rac1b did retain the ability to activate NF-kB, suggesting that the insert did not perturb all effector function. Therefore, we evaluated these and other Rac1 signaling activities and we found that Rac1b failed to activate SRF (not shown) or NF-kB transcriptional activity, or to stimulate transcription from the cyclin D1 promoter. Since our previous studies showed that lamellipodia induction, PAK binding, and JNK activation were dispensable for Rac1 transforming activity , the loss of these effector functions alone should not affect the transforming ability of Rac1b. However, our previous studies found that NF-kB-mediated stimulation of cyclin D1 expression best correlated with Rac1-transforming activity (Joyce et al., 1999) . Furthermore, we have determined that inhibition of NF-kB can block the growth of Rac1(61L)-transformed NIH 3T3 cells in soft agar (A Karnoub, G Reuther, and C Der, manuscript in preparation). One possible explanation for the discrepancy in our different conclusions regarding Rac1b and a failure to cause NF-kB activation may be that Matos et al. utilized a Q61L mutant of Rac1b in their assays (Matos et al., 2003) .
PI3K-dependent activation of AKT has been shown previously to be important for Rac1-mediated inhibition of differentiation and migration (Keely et al., 1997) and promotion of anchorage-independent growth (Coniglio et al., 2001) . We therefore decided to explore the possibility that Rac1b may promote AKT activation. We did, indeed find that Rac1b-activated AKT to levels comparable to that of Rac1(61L). Thus, it is possible that this is the pathway that contributes to Rac1b-mediated cellular transformation. Further analyses of the ability of Rac1b to stimulate other Rac1 effector functions, and a determination of whether Rac1b can bind to additional effectors, will be needed to clarify the exact mechanism by which Rac1b promotes transformation.
Our studies provide an initial indication that Rac1b, which seems to be selectively expressed in a number of carcinomas (Jordan et al., 1999; Schnelzer et al., 2000; Matos et al., 2003) , contributes to oncogenesis, in vivo. Unlike the mutationally activated Ras proteins found in human cancers, no equivalent point mutation-activated variants of Rac1 or other Rho GTPases have been identified in human cancers (Schnelzer et al., 2000; Boettner and Van Aelst, 2002; Jaffe and Hall, 2002; Sahai and Marshall, 2002) . Instead, the aberrant expression or activities of Rho GTPase regulators has been observed in human cancers. For example, we recently determined that Tiam1 is an effector of Rasmediated activation of Rac (Lambert et al., 2002) , and Collard and colleagues showed that loss of Tiam1 function greatly impaired Ras-mediated skin tumor formation in mice . In addition, activating point mutations have been found in the Tiam1 gene in a number of human renal cell carcinomas (Engers et al., 2000) . It appears, therefore, that rather than constitutive activation, accelerated GDP-GTP exchange may be more important for Rac1-mediated oncogenesis, as is the case for Rac1b. In addition, Seraj et al. (2000) have shown that loss of RhoGDI2 expression is associated with invasive and metastatic human cancers. Therefore, the inability of RhoGDI to interact with Rac1b is also consistent with a role for this splice variant in oncogenesis.
Questions that remain to be elucidated include a more thorough study of the signaling machinery that Rac1b utilizes to induce cellular transformation. Yeast two-hybrid or mass spectrometric analyses could be performed to determine if Rac1b interacts with unique binding partners. Whether Rac1b contributes to the transformed properties of carcinoma cell lines will be an essential avenue for investigation. Use of interfering or antisense RNA-mediated knockdown of Rac1b expression can be utilized to address this issue. Finally, what factors favor expression of the Rac1b splice variant message will also be important to determine.
Materials and methods
Molecular constructs
Mammalian expression vectors encoding wild-type (WT) human Rac1 and Rac1b cDNA sequences (pRK5-myc-Rac1/ Rac1b), a constitutively active Rac1(61L) mutant (pRK5-myc), and bacterial expression vectors encoding GST fusion proteins of Rac1 and Rac1b (pGEX-2T-GST-Rac1/ Rac1b) were described previously (Schnelzer et al., 2000) . The rac1 and rac1b cDNA sequences were amplified by polymerase chain reaction (PCR) with the oligonucleotide primers TTTTGGATCC ATGCAGGCCATCAAGTGTG and TTTACGGAC GACAACATTCCTAGGTTTT to introduce 5 0 and 3 0 BamHI restriction sites. The resulting fragment was then subcloned into the BamHI sites of the pCGN-hygro and pEGFP-C1 mammalian expression vectors. All cDNA sequences were verified by DNA sequencing. Expression of the inserted cDNA sequences in these constructs resulted in the addition of amino-terminal hemagglutinin (HA) epitope-and green fluorescent protein (GFP) sequences to each Rac1 protein, respectively. The rac1(61L) cDNA was also subcloned into pCGN-hygro. pZIP-raf(Y340D) encodes an amino terminal-truncated and constitutively activated variant of human Raf-1 and has been characterized previously (Khosravi-Far et al., 1995) . pGEX-GST-BCR-GAP encodes the catalytic domain of BCR which is a GAP for Rac1, Cdc42, and RhoA and has been characterized previously (Wennerberg et al., 2002) . pcDNA3-myc-Tiam1 C1199 encodes an amino-terminally truncated, constitutively activated mutant of Tiam1 and was obtained from G Bollag (Onyx Pharmaceuticals, Richmond, VA, USA) and has been characterized previously (Lambert et al., 2002) . pcDNA3.1-RhoGDIa was obtained from Dr Mark Philips (New York University). pcDNA3-myc-Rho-GDIa was obtained from Dr Bin Lim (Harvard). pCMV5-M2-Flag-JNK has been characterized previously . pCMV6M Pak1, pCDNA His3(T7) Pak5, pCMV6M Pak6 were obtained from Dr Jonathan Chernoff (Fox Chase Cancer Center). pRK5-myc-POSH-RBD encodes the isolated Rac1-GTP binding fragment from Posh, a Rac1-specific effector (Wennerberg et al., 2002) . Reporter constructs where the luciferase gene is under the control of minimal promoters with NF-kB (Galang et al., 1996) or SRF responsive elements, or the human cyclin D1 promoter (Albanese et al., 1995) have been described previously.
Protein expression and purification pGEX constructs encoding Rac1 WT, Rac1b and BCR-GAP were transformed into BL-21 Escherichia coli and protein expression was then induced by adding 1 mM IPTG and allowed to proceed for 4 h at 371C (for Rac1 WT and Rac1b) or for 24 h at room temperature (for BCR-GAP). Cells were pelleted by centrifugation at 5000 g for 15 min, then resuspended in 20 ml ice-cold lysis buffer (20 mM Tris, 6 mM EDTA, 50 mM MgCl 2 , 10mM GDP (for GTPases), 1 mM DTT, 1 Â BAL, 10 mg/ml Pefabloc, 2 mg/ml lysozyme, 2 mg/ml DNase and 0.01% NaN 3 ), sonicated, and then clarified by centrifugation. Glutathione-Sepharose beads (Amersham-Pharmacia Biotech) were washed and equilibrated with ice-cold lysis buffer. A volume of 500 ml of a 1:1 beads : lysis buffer slurry were then added to the 20 ml bacterial lysates and batch loading was carried out for 1 h at 41C. Beads were then pelleted by centrifugation and the supernatant was discarded. Beads were then washed three times in wash buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 10 mM GDP and 1 mM DTT) and stored at À201C until biochemical assays were to be performed.
Guanine nucleotide exchange assays
GST-Rac1 WT and GST-Rac1b were eluted from glutathionesepharose beads in elution buffer (20 mM HEPES pH 7.5, 5 mM MgCl 2 , 10 mM GDP, 1 mM DTT, 5% glycerol and 50 mM glutathione) by batch elution. Protein concentration was quantified by Bradford assay. Guanine nucleotide exchange was subsequently monitored as the increase in relative fluorescence of a fluorescent GTP analog (mant-GTP) upon binding either Rac1 or Rac1b in exchange for GDP. Prior to addition of bacterially expressed, purified catalytic fragments of Tiam1 (the tandem Dbl and pleckstrin homology (DH/PH) domains) or Vav2 (DH/PH/cysteine-rich domain (CRD)), 1 mM of each Rac1 protein was incubated with 200 nM mant-GTP in assay buffer (20 mM Tris pH 7.5, 50 mM NaCl, 10 mM MgCl 2 , 1 mM DTT 50 mg/ml BSA and 10% glycerol) at 201C, and fluorescence was measured using a Perkin-Elmer LS-50B (l ex ¼ 360 nm and l em ¼ 440 nm; slits ¼ 5/5 nm). After equilibration, 0.2 mM of isolated Tiam1 DH-PH, Vav2 DH/PH/ CRD or buffer was added.
Single turnover GTPase assays
GST-Rac1 WT and Rac1b bound to glutathione sepharose beads were incubated with 10 mM EDTA for 1 min at 41C. The GTPases were then loaded with GTP by incubating them with 1 mM GTP for 20 min at 41C, followed by the addition of 40 mM MgCl 2 . GTP-loaded proteins were washed four times in 20 mM Tris pH 7.5 and 1 mM MgCl 2 . Proteins were eluted with 100 mM glutathione in 20 mM Tris pH 8.0 and 1 mM MgCl 2 . Protein concentrations were quantified by Bradford assay. Single turnover GTP hydrolysis was monitored as a change in the relative fluorescence of MDCC-phosphate binding protein (MDCC-PBP) upon binding free inorganic phosphate (Kimple et al., 2003) . A measure of 2 mM MDCC-PBP plus 0.1 mM BCR-GAP was incubated in GAP assay buffer (20 mM Tris pH 7.5, 1 mM MgCl 2 ) at room temperature for 5 min in 96-well microtiter plates until fluctuations in MDCC-PBP fluorescence due to temperature change were minimized. Rac1 WT and Rac1b preloaded with 1 mM GTP were then added and GTP hydrolysis was monitored for 30 min. Assays were carried out in a 96-well plate reader fluorimeter (Spectromax Gemini, Molecular Devices) l ex ¼ 425 nm, l em ¼ 465 nm. Software analysis was carried out using Softmax Pro V. 4.6.
Transformation assays
NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum (designated complete growth medium). For primary focus formation assays, NIH 3T3 cells were cotransfected with 1 mg of either the empty pCGN-hygro vector or encoding Rac1b, Rac1 WT or Rac1(Q61L), together with 0.5 mg of either the empty pZIPNeoSV(x)1 vector or encoding the weakly activated Raf(Y340D) mutant using calcium phosphate precipitation. Cell cultures were maintained on complete growth medium and the formation of foci of transformed cells was analysed 21 days post-transfection. Cells were then fixed in 10% acetic acid, 10% methanol and stained using crystal violet dye. Secondary focus formation assays were performed using NIH 3T3 cells stably expressing the various pCGN-rac1 constructs described above. Cells expressing pCGN-hygro were used as a control. Positive selection was carried out using 200 mg/ml hygromycin in the growth medium for 14 days. Expression of the HA epitope-tagged Rac1 proteins was verified using an anti-HA monoclonal antibody (Covance). For secondary focus formation analyses, 10 5 parental NIH 3T3 cells were mixed with 10 5 of cells stably expressing the various Rac1 constructs. Cultures were maintained for 28 days on complete growth medium. The formation of foci was subsequently quantified and cells were fixed and stained as described above.
To assess anchorage-independent growth, 10 5 NIH 3T3 cells stably expressing empty pCGN-hygro or the various Rac1 constructs described above, were plated onto 60 mm Petri dishes in 0.6% bacto-agar (Becton, Dickinson and Co.) in complete growth medium. Colony growth was assessed 28 days later.
To assess growth rate on plastic and saturation density, 10 4 NIH 3T3 stably expressing each Rac1 protein, or stably transfected with the empty vector, were plated onto 60 mm dishes. Cells were then trypsinized and duplicate dishes were counted every 2 days over a 10-day period.
Confocal fluorescence microscopy
Rac1b interaction with Rho-GDIa activity was determined using an assay described by Michaelson et al. (2001) . MDCK cells were cotransfected with 1 mg of pEGFP empty vector or encoding Rac1b, Rac1 WT or Rac1(61L) together with 5 mg of either empty pRK5 or pRK5-Myc-RhoGDIa using Effectene Transfection Reagent (Qiagen). At 24 h post-transfection, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Anti-Myc (9E10) IgG mouse monoclonal antibody followed by Alexa594 conjugated anti-mouse secondary antibody were used to detect Myc epitope-tagged RhoGDIa expression. Confocal images were acquired using a Fluoview 300 laser scanning confocal imaging system (Olympus, Tokyo, Japan) configured with an IX70 fluorescence microscope fitted with a PlanApo Â 60 oil objective (Olympus). Fluorescent images, X-Y section at 0.28 mm, were collected sequentially at 800 Â 600 resolution.
Luciferase reporter assays
For transient transfection analyses, 1.25 Â 10 5 NIH 3T3 cells were plated in six-well plates. After 24 h, these cells were transfected with 1 mg pCGN-hygro empty vector or pCGN encoding the various Rac1 constructs described above (1 mg Rac1b, 0.5 mg Rac1 WT or 0.5 mg Rac1(61L)). Cells were cotransfected with either 0.5 mg NF-kB or cyclin D1 promoterluciferase constructs (see above). At 24 h post-transfection, cells were serum starved in growth medium supplemented with 0.5% calf serum for 18 h. Cells were then harvested, lysed and analysed for luciferase activity using enhanced chemiluminescence reagents and a Monolight 2010 luminometer (Analytical Luminescence). Expression levels of the various Rac1 constructs was assessed by immunoblotting using anti-HA antibody.
In vitro GEF, GDI and effector binding GST, GST-Rac1b and GST-Rac1 WT bound to glutathionesepharose beads were incubated with cell lysates of NIH 3T3 cells transiently expressing Myc epitope-tagged Tiam1-1199, Rho-GDIa, Pak1, and POSH-RBD. GST proteins bound to beads were washed and resuspended in MLB (25 mM HEPES pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 10% glycerol and 10 mM MgCl 2 ) containing 10 mM EDTA to facilitate release of GDP bound to the Rac1 proteins resulting in nucleotide-free proteins. For each binding assay, 10 mg of GST-Rac1b or Rac1 WT protein was used. Rac1b and Rac1 WT were then loaded with GMPPNP by incubating with 1 mM GMPPNP at 41C for 20 min. Rac1 proteins were then incubated with 20 mM MgCl 2 for 10 min at 41C. Nucleotidefree or GMPPNP-loaded Rac1 proteins bound to beads were then added to the NIH 3T3 cell lysates described above. Beads were washed three times in MLB and bound proteins were detected by SDS-PAGE followed by Western blotting using 9E10 anti-Myc monoclonal or anti-T7 (Bethyl Labs) polyclonal antibodies. Levels of GST-Rac1 WT and GST-Rac1b used in each pull down were determined by staining the PVDF membrane with Ponceau-S dye to verify that equal amounts of each GTPase were used.
JNK and AKT phosphorylation and activation
Activation of JNK was determined by determination of phosphorylation of JNK at residues Thr 183 and Tyr185 in cells expressing empty pCGN-hygro or pCGN-rac1b, Rac1 WT or Rac1(61L) was detected by SDS-PAGE followed by Western blotting using a monoclonal anti-phospho-SAPK/ JNK (Thr183/Tyr185) antibody (G8; Cell Signaling). Total JNK levels were determined using a polyclonal anti-JNK antibody (Cell Signaling). Activation of AKT was determined by determination of phosphorylation of AKT at Ser473 in cells transiently expressing pCGN-hygro pCGN-rac1b, Rac1 WT or Rac1(61L) was detected by SDS-PAGE followed by Western blotting using a polyclonal anti-phospho-AKT (ser 473) antibody (Upstate Inc.), following 48 h of growth in DMEM supplemented with 0.5% calf serum. Total AKT was detected using a polyclonal anti-AKT antibody (Upstate Inc.)
